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Abstract
Background: Polymeric fibronectin (polyFN) assembled on suspended breast cancer cells is required for metastasis.
Conceivably, drugs that target such polyFN may fight against cancer metastasis. While stilbene analogs trigger pro-
apoptotic effect on attached cancer cells, whether they prevent polyFN assembly and metastasis of suspended
cancer cells via an apoptosis-independent manner remains unexplored.
Methods: We depleted suspended Lewis lung carcinoma (LLC) cells of polyFN by silencing the endogenous FN
expression or pterostilbene (PS) to examine whether metastasis of lung cancer cells could thus be suppressed. We
investigated whether PS regulates AKT-ERK signaling axis to suppress polyFN assembly in suspended LLC cells
independently of apoptosis. We tested the therapeutic effects of orally administered PS against cancer metastasis.
Results: Both FN-silencing and PS among the three stilbenoids indeed significantly reduced polyFN assembly and
lung metastasis of suspended LLC cells in an apoptosis-independent manner. Mechanistically, PS-induced AKT
phosphorylation (pAKT) and suppressed ERK phosphorylation (pERK) in suspended LLC cells, whereas pretreatment
with a PI3K inhibitor, LY294002, effectively reduced pAKT, rescued pERK, and consequently reversed the PS-
suppressed polyFN assembly on LLC cells; these pretreatment effects were then overturned by the ERK inhibitor
U0126. Indeed, PS-suppressed lung metastasis was counteracted by LY294002, which was further overruled with
U0126. Finally, we found that PS, when orally administered in experimental metastasis assays, both significantly
prevented lung colonization and metastasis of LLC cells and reduced the already established tumor growth in the
mouse lungs.
Conclusions: PS suppressed AKT/ERK-regulated polyFN assembly on suspended LLC cells and pulmonary
metastasis. PS possesses potency in both preventing and treating lung metastasis of lung cancer cells in apoptosis-
independent and apoptosis-dependent manners, respectively.
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Background
Lung cancer is the leading cause of cancer deaths world-
wide [1, 2]. The majority of current cancer therapies
pursue the goal of a better cytotoxic effect on cancer
cells, aiming for tumorigenic suppression [3]. Unfortu-
nately, the outcomes of these therapeutic strategies often
ironically lead to increased mortality due either to the
subsequent drug resistance and to metastatic recurrence
or tumor cell dissemination within the circulation upon
surgical removal of tumor tissues [4]. This issue has put
scientists in a dilemma and has drawn worldwide atten-
tion. In complement with both primary tumor-targeted
cytotoxic approaches and surgical strategies, effective in-
hibition of metastases by means of post-operational
measures against circulating tumor cells (CTCs), even
including those that are insensitive to cytotoxic therap-
ies, may alternatively be an ideal anti-cancer adjuvant
strategy [5, 6]. However, not enough attention has been
devoted to developing this therapeutic modality against
lung cancer.
Prior to metastasis, extracellular matrix (ECM) proteins
contribute to the primary tumor or circulatory microen-
vironments that eventually facilitate efficient colonization
of blood-borne tumor cells in distant organs [7, 8].
Tumor-associated ECM, including collagen and fibronec-
tin (FN), is characterized by the polymerization of
fibrillar components on tumor cell surfaces both in ad-
herent and in suspended statuses [8–11]. During FN
polymerization, disulfide-bonded dimer FN is polymer-
ized into mature polymeric FN (polyFN) through a self-
assembly process that is mediated by other covalent
bonds than the disulfide bond [12]. Such polyFN is mor-
phologically formed on suspended tumor cell surfaces as
randomly distributed puncta [10, 11, 13]. The vascular
arrest and metastasis of CTCs in the lungs are funda-
mentally mediated by the binding between endothelial
dipeptidyl peptidase IV (DPP IV) and polyFN assembled
on tumor cell surfaces [10, 13, 14]. It is the mature and
irreducible polyFN that is assembled on suspended
tumor cell surfaces remains on the well-top of SDS-
PAGE stacking gel (GT) [10] and exposes the otherwise
cryptic DPP IV-binding sites [13] mediates the binding of
DPP IV and lung metastasis [10]. Clinically, FN expres-
sion has been identified as one of the prognostic bio-
markers in CTCs of non-small cell lung cancer (NSCLC)
and pancreatic cancer patients [15–17]. Consistently, FN
expression in gastric cancer cells and invasive breast can-
cer cells has also been strongly correlated to poor prog-
noses and low survival rates [18, 19]. Thus, metastatic
CTC-associated FN has a potential to serve as an anti-
cancer therapeutic target [20]. Although an investigation
into responsible signaling mechanisms has shown that
protein kinase Cε is involved in the regulation of
polyFN assembly on suspended tumor cells and
consequently results in pulmonary metastasis [11], other
participating signaling regulators remain largely elusive. A
mechanistic elucidation of polyFN-depleting reagents in
metastatic suppression may help unveil undiscovered
pathways in regulating polyFN assembly.
Phytochemical agents have often been used as alterna-
tive medicine as an attempt to improve the traditional
cancer therapeutic consequences [21]. Stilbenoids,
hydorxylated derivatives of stilbene including resveratrol,
oxyresveratrol, and rhapontigenin, are a group of natural
compounds existing in ripened blueberries and grapes
[22]. During the past decades, numerous studies have
found that, due to structural homology, most stilbenoids
possess similar biomodulatory functions including anti-
oxidative and anti-inflammatory effects [23]. In addition,
resveratrol displays anti-tumor activity [24]. Among the
resveratrol analogs, pterostilbene (PS) has a higher bio-
availability and is more lipophilic, leading to better oral
absorption and cellular uptake [23]. Despite preclinical
evidence revealing that these dietary compounds sup-
press lung tumorigenesis through triggering apoptosis in
tumor cells [23], little is known about how or even
whether or not they can effectively prohibit blood-borne
tumor cells from colonizing the lungs by depleting the
polyFN on their surfaces without causing apoptosis.
Therefore, the purposes of this study were to validate
the role of polyFN in the lung metastasis of Lewis lung
cancer cells (LLCs), to examine the ability of stilbene de-
rivatives to prevent polyFN assembly of suspended LLCs
and suppress lung metastasis in both in vitro and in vivo
settings, and to explore the underlying apoptosis-
independent pathway responsible for the polyFN-
depletion by stilbene derivatives. Our results clearly
demonstrated that silencing endogenous FN expression
in suspended LLCs significantly reduced their polyFN
assembly and pulmonary metastasis. In line with these
results, PS, among the three other stilbene derivatives,
effectively suppressed polyFN assembly and inhibited the
pulmonary metastasis of various suspended tumor cells,
including LLCs, in an apoptosis-independent manner.
Mechanistically, the polyFN-depletion by PS was medi-
ated by a signaling pathway involving AKT/ERK cascade.
Importantly, PS by oral gavage both significantly reduced
pulmonary metastasis and growth of LLC cells in the
lungs in the experimental metastasis models.
Methods
Reagents
The four stilbenoids (pterostilbene, resveratrol, oxyres-
veratrol, and rhapontigenin) were obtained from Sabinsa
Corp. (East Windsor, NJ). The purity of four compounds
was determined by high-performance liquid chromatog-
raphy as higher than 98%. 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), CaCl2, HEPES,
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paraformaldehyde (PFA), and crystal violet from Sigma-
Aldrich, Inc. (St. Louis, MO, USA) and Carboxyfluores-
cein succinimidyl ester (CFSE) and Hoechst 33258 were
from Invitrogen (Carlsbad, CA, USA). ERK inhibitor
U0126, PI3K inhibitor LY294002 (LY), and bovine serum
albumin (BSA) were from Cyrusbioscience (Taipei,
Taiwan). Monoclonal antibodies (mAbs) against ERK1/2,
pERK1/2, AKT, pJNK, JNK, and pp38 were from Cell
Signaling (Beverly, MA, USA). 6A3 mAb was home-
made [10, 25]. Polyclonal antibodies (pAbs) against
pAKT, p38, and GAPDH were from Biolegend (San
Diego, CA, USA); anti-FN pAb was obtained from
Sigma-Aldrich, Inc. (St. Louis, MO, USA). Annexin V-
FAM apoptosis detection reagent was from LEADGENE
(Tainan, Taiwan). Purified DPP IV (31–767) was prepared
from lungs of Fischer 344 rats as described in our previ-
ous publication [26].
Cell culture
LLC cell line (ATCC: CRL-1642) was from the American
Type Culture Collection. CNS-1 cells used to generate
CNS-1 TR50 cells and human metastatic lung cancer
CL1-5 cells were generous gifts from Dr. Chun-I Sze
[Department of Cell Biology and Anatomy, National
Cheng Kung University (NCKU)] and Dr. Yi-Ching
Wang (Department of Pharmacology, NCKU), respect-
ively. All cell types were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco BRL, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS)
(Gibco BRL, USA). End-over-end (EoE) suspension cul-
ture was performed as previously described [11]. Tissue
culture plastic ware was either purchased from BD
Falcon (Franklin Lakes, NJ, USA) or from Wuxi NEST
Biotechnology Co., Ltd (Wuxi, Jiangsu, China).
Generation of lentivirus and small hairpin RNA (shRNA)
interference
The RNAi reagents for lentiviral vector system were
from the National RNAi Core Facility supported by the
National Research Program for Genomic Medicine
Grants of NSC (NSC 100-2314-B-006-055). The mouse
library is referred to as TRC-Mm 1.0. Individual clones
are identified as shRNA TRCN00000231750 for SCR
control, TRCN00000306574, and TRCN0000090371 for
FN-silencing shFN#1 and shFN#2, respectively; and
TRCN0000022936 and TRCN0000302357 for AKT-
silencing shAKT#1 and shAKT#2, respectively. The len-
tiviruses for RNAi techniques were produced as previ-
ously described [27].
Animals and in vivo metastasis assays
All experiments on mice were performed according to
the guidelines of our institute (the Guide for Care and
Use of Laboratory Animals, NCKU Medical College).
Four-week-old male C57BL6 mice were acquired from
the Animal Center of the NCKU Medical College and
were housed by five per cage at 24 ± 2 °C and 50 ± 10%
relative humidity and were subjected to a 12-hour light/
12-hour dark cycle. In experimental metastasis assays
[14], LLC cells were treated according to individual de-
sign and were intravenously injected into C57BL6 mice.
The lung tissues were dissected and subjected to H&E
staining for further histological examination on meta-
static tumor nodules. For tumor colonization assays,
similar treatments of LLC cells to those for experimental
metastasis assays were labeled with 20 μM CFSE at
37 °C for 30 min prior to the intravenous injections.
Mice were sacrificed 30–36 h after tumor cell injec-
tions. Mouse lungs were removed and subjected to
lung vasculature perfusion with PBS. The images of
lung-colonized CFSE-labeled LLC cells were taken by
Multiphoton Confocal Microscope BX61WI (FV1000MPE;
Olympus, Tokyo, Japan) and were subjected to quantifica-
tions with ImageJ software.
Evaluation for the therapeutic effects of orally
administered PS on cancer metastasis
C57BL6 mice orally received DMSO vehicle or 5 mg/kg
of PS (twice/day) 2 h prior to intravenously inoculation
of 5 × 105 LLC cells that were recovered in 20% FBS/
DMEM for 2 h at 37 °C and then the daily PS-
feeding schedule was continued for two more days.
Alternatively, PS-feeding was scheduled from the fifth
day after LLC inoculation to the end of the experi-
ment. Tumor nodules in the lungs of the sacrificed
mice were photographed, counted, and subjected to
H&E staining.
Cell viability assays
The treated adherent LLC cells were subjected to MTT
assays as previously described [28]. Alternatively, LLC
cells seeded in 96-well plates were subjected to 5 μg/ml
of UV-excited Hoechst 33258 dye that was used to stain
the cell nuclei in live cells 5 h before each time point. At
the end point of each experiment, 1 μg/ml of non-cell
permeable propidium iodide (PI), together with Hoechst
33258 dye, was added into the wells to stain the dead or
the damaged cells. Both Hoechst 33258 dye-positive and
PI-positive LLC cells were imaged.
FACS analysis for apoptotic LLC cells
The DMSO or PS-treated LLC cells either in adherent
or suspended statuses were subjected to Annexin V-
FAM and PI apoptosis detections for 20 min at room
temperature according to the manufacturer’s instruction.
After PFA fixation, apoptotic cells were quantified with
FACS analysis (FACSCalibur, BD Biosciences, CA, USA)
as previously described [11].
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Immunofluorescence staining
LLC cells in EoE suspension culture after various treat-
ments were subjected to immunofluorescence staining
for polyFN assemblies as previously described [11].
Protein preparation and western blotting
Total LLC cellular protein lysates of EoE suspension
culture were prepared as previously described [10].
ProteoJET™ Membrane Protein Extraction Kit (Thermo
Inc., San Jose, CA, USA) was used to prepare cyto-
solic and membrane protein extracts according to
manufacturer’s instruction. Protein samples were then
subjected to SDS-PAGE, electrotransferation, and
western immunoblotting (IB). The chemiluminescence
images of IBs were developed with CyECL reagents
(Cyrusbioscience, Taipei, Taiwan) according to the
manufacturer’s instruction.
Wound-healing assay
LLC EoE suspension cultured cells were treated with dif-
ferent concentrations of PS for 4 h and seeded onto 6-
well plates. Confluent adherent cells were then carefully
scratched to mimic a linear “wound” in monolayer cells
using a plastic pipette tip. After 48 h, the number of the
cells that migrated into the initial cell-free zone was
counted under microscope, based on the wounding edge
at time zero.
Transwell migration assay and matrigel invasion assay
The same LLC EoE suspension cultured cells as that for
wound healing assays were seeded onto transwell inserts
(8-μm pore, BD Falcon, Franklin Lakes, NJ, USA) in
which 20-μg Matrigel (BD Falcon) was absent for migra-
tion assays and precoated for invasion assays as previ-
ously described [14].
Image quantification methods
ImageJ software that was developed at the National
Institutes of Health and is freely available from internet
was used to quantify all the images of immunofluores-
cence staining and IB blotting. The statistical analyses
for the images were applied in at least three repeated
experiments.
Statistical analysis
Data derived from at least three separate experiments
are expressed as the mean ± SD. Statistical significance
was determined by using Student’s t test for comparison
between the means or one-way analysis of variance with
post hoc Dunnett’s test [29]. Differences were considered
to be significant when p value <0.05 (*), p < 0.01(**), or
p < 0.001(***).
Results
PolyFN assembly on suspended LLC cells is required for
pulmonary metastasis
We employed shRNA-mediated FN gene silencing to
investigate how endogenous FN expression contributes
to the polyFN assembly on suspended lung cancer
cells. Since covalently cross linkage in addition to di-
sulfide bond occurs during the maturation of polyFN
[10], that FN shRNAs (shFN#1 and shFN#2) treat-
ments significantly decreased polyFN in suspended
LLC cells under reducing conditions as represented by
FN on GT (Fig. 1a, b) suggested the requirement of
endogenous FN expression for FN polymerization dur-
ing matrix assembly. Next, we demonstrated the
polyFN puncta on suspended control and scramble
shRNA (Scr), but not shFN#2, LLC cells (Additional
file 1: Figure S1a; upper panel). The quantifications of
polyFN puncta (Additional file 1: Figure S1a; lower
panel) reconfirmed that the essential role of endogen-
ously synthesize FN in polyFN assembly on suspended
LLCs. Importantly, the FN-silencing did not result in
significant growth difference from control and Scr
LLC cells (Additional file 1: Figure S1b), suggesting
that depletion of polyFN on suspended LLC cells does
not affect cell viability, negating the possibility that the
metastatic consequences are indirectly influenced by
the death and/or prohibited the growth of polyFN-
depleted LLC cells.
Next, we examined the role of polyFN on suspended
LLC cells in pulmonary metastasis. We found that the
averaged ratio of lung weight over body weight
(LW:BW) (Additional file 1: Figure S1c, d) and lung
tumor nodule numbers (Fig. 1c, d) upon mouse sacri-
fices was significantly decreased for mice intravenously
receiving shFN#2 LLC cells as compared to those re-
ceiving control or Scr LLC cells. Histological observa-
tion revealed that the tumor nodules present in the
mouse lungs of both control and Scr groups, but not
the shFN#2 group, were quantitatively numerous with
diverse nodule sizes (Fig. 1e and Additional file 1:
Figure S1e). These results clearly supported that
polyFN assembly is required for pulmonary metastasis
of circulating tumor cells, and depletion of polyFN on
suspended tumor cells may be a useful polyFN-targeted
anti-metastatic strategy.
PS is among the other stilbenoids that are most potent in
depleting suspended tumor cells of polyFN by interfering
transportation of FN across plasma membrane
We next tested four structurally related stilbenoids in-
cluding resveratrol, oxyresveratrol, rhapontigenin, and
PS, for their effects on polyFN-depletion from sus-
pended LLC cells. PS was the most potent suppressor
(Additional file 1: Figure S2a) to deplete LLC cells of
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polyFN in a dose- and time-dependent manner (Fig. 2a–f
and Additional file 1: Figure S2b). Fluorescence
visualization confirmed the prominent effect of PS on the
polyFN-depletion (Additional file 1: Figure S2c). In
addition to LLC cells, PS also significantly depleted the
polyFN of suspended CL1-5 cells isolated from the tumor
tissues of a human non-small cell lung cancer patient [14]
(Additional file 1: Figure S2d) and suspended rat
FNhigh-CNS-1 glioblastoma cells derived from a
paclitaxol-resistant parental CNS-1cell line (Additional
file 1: Figure S2e), suggesting that the polyFN-
depletion effect of PS is not merely specific to sus-
pended LLC cells and may be more widely applied to
various metastatic and even chemo-resistant cancer
types for therapeutic purposes.
Interestingly, the monoFN, unlike the effect of FN-
silencing (Fig. 1b; right panel), was increased upon treat-
ment of PS (Fig. 2a, c, d, f ), suggesting that the dimin-
ished polyFN by PS is due to the prevention of monoFN
from being polymerized and assembled into polyFN. We
further investigated the underlying molecular mechan-
ism. Fractionation of plasma membrane and non-
membrane (cytoplasm) proteins from the PS-treated sus-
pended tumor cells revealed that PS markedly reduced
polyFN and, to a lesser extent, monoFN in plasma mem-
brane, but significantly increased monoFN in the cyto-
plasm compartments (Fig.2g–i), suggesting that the
suppression of polyFN by PS (Fig. 2a, c, d, f and
Additional file 1: Figure S2) is mainly due to the inhib-
ition of intracellular monoFN being transported onto
the extracellular plasma membrane of tumor cells and
subsequent polymerization into polyFN.
Apoptosis does not contribute to polyFN-depletion from
suspended LLC cells by PS
Since PS has long been known to be capable of inducing
apoptosis of adherent tumor cells [23], it is possible that
the depletion of polyFN on suspended LLC cells by PS
was a consequence of tumor cell apoptosis. To test this
possibility, we compared the apoptotic effects of PS on
suspended and adherent LLC cells in a time-course
study. While PS did not affect LLC viability in sus-
pension even at a concentration as high as 100 μM
for 24 h (Fig. 3a and Additional file 1: Figure S3), it
significantly induced apoptosis of adherent LLC cells
in a dose-dependent manner (Fig. 3b and Additional file
1: Figure S4). To firmly ensure that the PS-pretreatment
does not influence the long-term viability of suspended
Fig. 1 Endogenous FN expression is required for polyFN assembly on suspended LLC cells, which promotes lung metastasis. a The IB was probed
with anti-FN pAb (upper and middle panel) or anti-GAPDH (lower) as input control for the whole cell lysates of LLC cells alone (control) or LLC cells
expressing Scr shRNA (Scr) or FN shRNAs (shFN#1 and shFN#2) that were resolved in SDS-PAGE under reducing conditions. The polyFN means
polymeric FN form (upper panel) and monoFN monomeric FN form (middle panel). GT means well-top of stacking gel. b The quantifications of
expression levels of polyFN (% polyFN; left panel) and monoFN (% monoFN) by ImageJ software as normalized with expression levels of GAPDH.
c Tumor nodule numbers on mouse lung surfaces were counted, and d mouse lungs were taken from mice that intravenously received LLC cells
as described in (a) upon mouse sacrifices. e H&E staining for tumor nodules in mouse lungs in (d). Two representative lungs of each group were
demonstrated. Note: arrow heads depict tumor nodules in the lungs
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LLC cells, we reseeded the vehicle- or PS-pretreated sus-
pended LLC cells on the culture dishes and showed no
difference for the cell growth and migratory activities
(Additional file 1: Figure S5). Altogether, these results sug-
gested that polyFN-depletion from suspended LLC cells
by PS is not indirectly caused by apoptosis.
PS effectively inhibits pulmonary metastasis of LLC cells
Since polyFN is required for endothelial DPP IV binding
and lung metastasis of suspended LLC cells (Fig. 1a)
[10], we next tested whether PS suppresses lung metas-
tasis. We first demonstrated that treating suspended
LLC cells with PS inhibited the binding of a soluble DPP
IV (31–767) peptide possessing FN-binding ability [26] to
polyFN (Fig. 4a), entertaining the possibility that PS
could prevent circulatory tumor cells from adhering to
the lung vasculature. We then tracked prelabeled indi-
vidual LLC cell suspension and assessed the initial ex-
travasation. Indeed, the ability of PS-treated LLC cells to
colonize and to extravasate the mouse lungs was drastic-
ally reduced in a dose-dependent manner (Fig. 4b). We
next examined whether PS reduces lung metastasis of
suspended LLCs. The LW:BW ratios (Fig. 4c and
Additional file 1: Figure S6a) and lung tumor nodules
(Fig. 4d, e and Additional file 1: Figure S6b, c) were sig-
nificantly decreased in PS-treated groups compared to
the NC group. These results clearly demonstrated that
PS effectively prevented polyFN assembly on LLC cells,
reduced the lung colonization, and inhibited lung
metastasis. Treating suspended LLC cells with PS at
non-cytotoxic doses neither affected their motility as
revealed by wound healing assays (Additional file 1:
Figure S5), trans-well migration assays (Additional file 1:
Figure S7a) nor their invasiveness as revealed by matri-
gel invasion assays (Additional file 1: Figure S7b), sug-
gesting that the in vivo anti-metastatic effect of PS is not
attributed to the suppression of migratory/invasive abil-
ities of LLC cells. Nevertheless, these data did not ex-
clude possibilities that PS inhibits cancer metastasis
through polyFN-independent mechanisms [21–23].
PS suppresses the polyFN assembly of suspended LLC
cells by interfering with the AKT/ERK signaling pathway
We continued to ask how PS affects the signaling that
regulates the polyFN assembly on suspended LLCs.
Phosphorylation of intracellular proteins, including
PI3K/AKT and MAPK signaling pathways, has been
deemed an essential protein modification that facilitates
Fig. 2 PS depletes suspended LLC cells of polyFN by interfering transportation of FN across plasma membrane. a IBs were probed with anti-FN
pAb for lysates of LLC cells treated without or with various concentrations of PS for 4 h in suspension as indicated to reveal polyFN and monoFN
expressions and anti-GAPDH mAb for the normalization purposes. Quantifications of polyFN (b) and of monoFN (c) that were normalized by
GAPDH levels in (a). d–f Similar IBs and quantifications for the polyFN and monoFN as those in (a)–(c) of the lysates of suspended LLC cells
treated with 100 μM of PS for different time points. g IBs were probed for polyFN, monoFN, tubulin as a marker for the cytoplasm fraction, and
EGFR as a marker for the cell membrane fraction prepared from lysates of suspended LLC cells treated without or with 100 μM of PS. Quantifications
of polyFN and monoFN in the cytoplasmic fractions (h) and in the cell membrane fraction (i)
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tumor progression and metastasis [30]. Therefore, we
examined the modulatory effects of PS on the phosphor-
ylation of PI3K/AKT, JNK, p38, and ERK in suspended
LLC cells. We found that 4 h of PS-treatment signifi-
cantly increased AKT phosphorylation (pAKT) and con-
comitantly decreased ERK phosphorylation (pERK) in
suspended LLC cells in a dose-dependent manner
(Fig. 5a–e), whereas no difference was observed in the
phosphorylation statuses of JNK and p38 (Additional
file 1: Figure S8a–d). These results were different from
what have been found for adherent cells [22] and at-
tached LLC cells (Additional file 1: Figure S8e–g) and
raised the possibility that PS-activated PI3K/AKT sig-
naling inhibits ERK phosphorylation [31], thereby
interrupting the polyFN assembly on suspended LLCs.
LY294002 (LY), a common specific inhibitor of PI3K
that directly regulates pAKT, and AKT shRNAs
(shAKT#1 and shAKT#2) (Additional file 1: Figure S8i–j)
were used to test this possibility. We showed that pretreat-
ment with 10 μM LY effectively blocked the PS-induced
pAKT in LLC cells (Fig. 6a, b and Additional file 1:
Figure S9c). Meanwhile, it completely recovered the
PS-decreased pERK (Fig. 6a, c and Additional file 1:
Figure S9d) and polyFN levels (Fig. 6a, d, e, and Additional
file 1: Figure S9a, b), substantiating that PS-inhibited ERK
activity and subsequently polyFN assembly are both medi-
ated by the elevated pAKT in LLC cells. In line with the
effect of LY (Fig. 6a–e), immunofluorescent staining re-
sults confirmed the preventive effects of shAKT#1 and #2
on the assembly of polyFN puncta in the PS-treated LLC
cells (Additional file 1: Figure S9e, f and Fig. 6f, g).
Moreover, the requirement of PS-promoted pAKT for
the lowered pERK was reconfirmed by transfecting the
LLC cells with shAKT#1 prior to the PS-treatment
(Fig. 6h–l). We next employed an ERK inhibitor
U0126 in the PS-treated LLC cells (PS alone) and
found that the LY-rescued pERK (Fig. 7a, b) and
polyFN assemblies (PS + LY) (Fig. 7c, d) were re-
abolished (PS + LY + U0126) (Fig. 7a–d), confirming
that PS-depleted polyFN assembly is mediated by the
AKT-induced inactivation of ERK in LLC cells. Strik-
ingly, the LY-recovered LLC metastasis that was inhib-
ited by PS was drastically re-suppressed by U0126
(Fig 7e and Additional file 1: Figure S10). These find-
ings further corroborated that the PI3K/AKT/ERK sig-
naling axis is involved in the PS-suppressed polyFN
assembly and metastasis of circulating tumor cells.
Orally administered PS suppresses lung metastasis of LLC
cells
Since PS is one of the phytochemical agents that have
often been orally used as an alternative medicine for
tumor treatment, we tested whether tumor metastasis
could also be prevented via oral administration of PS.
We found that lung metastasis of LLC cells was signifi-
cantly reduced when PS was orally administered 24 h
prior to the intravenous inoculation of LLC cells and
was given twice a day for two more days to maintain the
Fig. 3 PS triggers apoptosis of LLC cells in adherent, but not suspended, status. a Suspended LLC cells treated with DMSO or various
concentrations of PS in a time course (0–24 h) were stained with Hoechst and incubated with PI at each time point as indicated in centrifugation
tubes. % cell viability was calculated as 1-PIhigh cell number/ Hoechsthigh cell number (left panel). Right panel: representative images showing the
co-staining of Hoechst and PI in PS-treated suspended cells at the 24-h time point. b Adherent LLC cells were similarly treated with DMSO or PS
and stained as in (a) within the culture dishes. Cell death % was calculated as PIhigh cell number/ Hoechsthigh cell number (left panel). Right panel:
representative images showing the co-staining of Hoechst and PI in PS-treated adherent cells at the 24-h time point
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Fig. 5 PS dose-dependently increases AKT phosphorylation and reduces ERK phosphorylation of suspended LLC cells. a IBs were probed for
various signaling proteins, and their phosphorylation statuses as indicated in the lysates of suspended LLC cells were treated without or with
various concentrations of PS for 4 h at 37 °C. Quantifications of ERK (b), pERK (c), AKT (d), and pAKT (e) were normalized by GAPDH levels in (a)
Fig. 4 PS effectively prevents LLC cells from binding to DPP IV and colonizing and metastasizing to the lungs. a Suspended LLC cells treated with
DMSO (control) or 100 μM PS were subjected to the binding of DPP IV (31–767) that was derived from full-length DPP IV and retained the polyFN-
binding ability. The cells were then subjected to IF staining using 6A3 mAb and phycoerythrin-conjugated goat anti-mouse antibody. The
averaged red fluorescence intensities (absolute DPP IV-binding levels) of representative cell images as circled with white dashed lines (left two
panels) were quantified in the right panel. b Representative images (left three panels) and quantifications (right panel) of mouse lung-colonized
suspended LLC cells that were treated with DMSO, 75 μM or 100 μM PS. Circled dots with dashed lines represent the colonized LLC cells labeled
with CFSE dye as illustrated with ImageJ software. c Lung weight/body weight (LW:BW) of the lungs in mice intravenously receiving LLC cells
treated with DMSO (control) or two concentrations of PS upon mouse sacrifices. Mouse lungs (d) were taken and tumor nodule numbers (e) on
lung surfaces from mice as described in (c) were counted upon mouse sacrifices. Black arrow heads depict tumor nodules in the lungs
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PS in the circulation (Fig. 8a–c). These results indicated
that the prevention of tumor cell extravasation within
the circulation of the lungs could be accomplished by
orally giving PS. Interestingly, the already-established
metastasis was also decreased when PS was orally given
5 days after LLC inoculation, and the treatment was
continued twice a day until the mice were sacrificed
(Fig. 8a–c), suggesting that PS evokes cytotoxic effects
on the extravasated tumor cells in adherent status in the
lungs. Indeed, this notion was supported by the histo-
pathological findings in which more inflammatory re-
sponses were often observed (Fig. 8c). Altogether, our
findings promisingly shed light on PS that might serve
as an alternative phytochemical medicine with prevent-
ive as well as therapeutic values for late stage cancer pa-
tients due to its multiple anti-metastatic effects (Fig. 9).
Discussion
FN has been regarded as an anti-cancer therapeutic tar-
get [15, 20]. We have shown that polyFN assembled on
blood-borne cancer cells facilitates cancer metastasis in
the lungs [11, 13, 25]. Consistently, anti-polyFN and
anti-DPPIV strategies have been verified in cancer meta-
static prevention [13, 25]. Using RNAi techniques, the
present study is the first to employ an experimental me-
tastasis model to reveal that depleting circulating lung
tumor cells of polyFN could serve as a therapeutic strat-
egy against metastasis. Furthermore, our findings that
PS, a well-known phytochemical, significantly inhibited
the polyFN assembly and lung metastasis of blood-borne
lung cancer cells strongly suggest that the anti-FN strat-
egy for cancer patients is potentially applicable in meta-
static prevention and prognostic improvement.
Fig. 6 PS inhibits pericellular FN polymerization via triggering AKT phosphorylation which reduces ERK phosphorylation. a IBs were probed for
AKT phosphorylation, ERK phosphorylation, polyFN, and monoFN in lysates of suspended LLC cells treated without or with 100 μM of PS, 10 μM
of PI3K inhibitor LY294002 (LY) or mixture of both for 4 h in suspension. Quantifications of pAKT (b), pERK (c), polyFN (d), and of monoFN (e) that
were normalized by GAPDH levels in the IBs in (a). f Representative images of IF staining for the polyFN assemblies on suspended LLC cells
transfected with Scr or shAKT#1 and 2 in the absence or presence of 100 μM of PS for 4 h. g Quantifications of polyFN levels on LLC cells as the
treatment in (f). h The same IBs as in (a) for lysates of suspended LLC cells transfected with Scr shRNA or shAKT#1 in the absence or presence of
100 μm of PS for 4 h. Quantifications of AKT (i), pAKT (j), ERK (k), and pERK (l) were normalized by GAPDH levels in the IBs in (h)
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Endogenous synthesis of FN has been found to be re-
quired for the polyFN assembly on breast cancer cells
[11]. Here, we also showed the same requirement for the
lung cancer cells to assemble polyFN (Fig. 1). However,
the preventive effect of PS on the translocation of intra-
cellular dimeric FN onto the extracellular compartment
of LLC cells (Fig. 2) suggested that the mechanism in-
volved in the depletion of polyFN by PS is not due to
the transcriptional inhibition of FN biosynthesis, but in-
stead to the prevention of cell surface localization of di-
meric FN to be later polymerized into polyFN.
Consistent with our results, it has been shown that the
newly synthesized FN is a disulfide-bonded dimer which
is relatively deoxycholate (DOC)-soluble and can be eas-
ily reduced into monoFN by reducing reagents, whereas
the polyFN in its polymeric status becomes DOC-
insoluble and non-reducible [32]. A possible explanation
for such phenomenon is that, during FN translocation
between the rough endoplasmic reticulum (RER) and
Golgi complexes, monoFN could be dimerized merely
through two C-terminal disulfide bonds [32], whereas
plasma membrane-located dimeric FN could further be
polymerized through intermolecular disulfide bonds
[32], and covalent bonds most likely triggered by cell
surface tissue transglutaminase not present within the
RER/Golgi compartments [33].
It has been recognized that anoikis is triggered
through a significant inactivation of the PI3K/AKT sur-
vival signal pathway when normal cells lose their adhe-
sions to the surrounding ECM and commit to apoptosis
[34]. However, the blood-borne metastatic tumor cells
evolve to be anoikis-resistant, and the PI3K/AKT sur-
vival signals persist in the absence of ECM anchorages
[34, 35]. Consistently, we showed that the PS-treated
lung tumor cells in suspension, where the sustained
AKT signal was further activated, failed to colonize and
metastasize to the lungs within the circulation but sur-
vived well (Figs. 2, 3, 4, 5, 6, 7), which was apparently
distinct from those effects of PS on adherent cells as
manifested by the AKT inactivation and apoptosis [23].
Fig. 7 The activated PI3K/AKT-induced ERK inactivation mediates the inhibitory effect of PS on polyFN polymerization on and mouse lung
metastasis of suspended LLC cells. a IBs were probed for total ERK, pERK, and GAPDH in lysates of suspended LLC cells treated without or with
100 μM of PS, PS + 20 μM of PI3K inhibitor LY or PS + LY+ 20 μM of ERK inhibitor U0126 for 4 h in suspension. Note: Images of the same proteins
were trimmed from the same IB gels. b Quantifications of pERK that was normalized by GAPDH levels in the IBs in (a). c Representative images of
IF staining for the polyFN assemblies on suspended LLC cells that were treated similarly as described in (a). The positions of tumor cells were
circled with white dashed lines. d Quantifications of polyFN levels on LLC cells that were treated as in (c). e Mouse lungs (upper panel) were taken,
and tumor nodule numbers (lower panel) on lung surfaces from mice bearing the intravenously inoculated LLC cells that were treated with
DMSO, PS, PS + LY or PS + LY + U0126 as described in (a) were counted upon mouse sacrifices
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Due to the entirely distinct extracellular microenviron-
ments between adherent and circulating tumor cells [6],
the signaling pathways in the tumor cells within such
distinct microenvironments conceivably also differ even
when responding to the same drug treatment. Since
AKT activity has been reported to be involved in pro-
moting multiple tumor functionalities in addition to trig-
gering cell proliferation and survival [36], it is expected
that PS suppresses the polyFN of suspended tumor cells
via the AKT/ERK signaling axis independently of apop-
totic inhibition. It has been proposed that PS may cause
apoptosis in adherent cells by directly binding to one of
the various intracellular target molecules, including
CYP1A1, CYP1A2, CYP1B1, and metastasis-associated
protein 1 (MAP-1) [37, 38]. In line with this concept, PS
might bind to the same downstream target molecules to
suppress metastasis of blood-borne tumor cells in an
apoptosis-dispensable manner [39, 40].
Fig. 9 Schematic illustration for the roles of orally administered PS in metastatic suppressions either via polyFN-depletion and prevention of lung
colonization of circulating tumor cells or via triggering apoptotic effect on adherent tumor cells that have already been established in the lungs
Fig. 8 Oral administration of PS prevents lung-colonization of intravenously inoculated tumor cells and suppresses the growth of already established
tumor nodules in the lungs. a Tumor nodules in the lungs of the sacrificed mice who orally received DMSO vehicle or 5 mg/kg of PS (twice/day) from
before to after (before and after) or 5 days after (after) intravenously inoculation of 5 × 105 LLC cells that were recovered in 20% FBS/DMEM for 2 h at
37 °C. The mice were sacrificed 30 days after tumor injection. b Representative mouse lungs with tumor nodules and their H&E staining from the mice
as described in (a). c Microscopies of the H&E staining of mouse lungs as described in (b). Note: * means p value <0.05. Red lines in the magnitudes of
40×, 100×, and 400× mean 200, 100, and 20 μm, respectively. Arrow heads mean the tumor nodules in the lungs. Arrows mean the apparent apoptotic
tumor cells with fragmented DNAs
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Combination therapies have recently prevailed over
single drug treatment, particularly for cancer patients
suffering late stages of malignancy [41]. The essence of
most combinatory drugs for cancer therapeutics is to
prevent cancer cell resistance to apoptosis-inducing
drugs [41]. However, cancer cells still tend to develop re-
sistance to apoptotic assaults and become even more
metastatic [42, 43]. It is desired that combinatory drugs
alternatively attack other later progression steps than the
original tumor cell growth [44, 45] to complement
traditional chemotherapeutics or to fight with
chemoresistance. Importantly, preferred drugs are
desired to exert multiple functions by concomitantly
inducing apoptosis of tumor cells in the solid tumor
tissues and triggering apoptosis-independent mecha-
nisms to prevent metastasis of CTCs. Here, we found
that PS fulfilled such a desire for multiple functional-
ities (Fig. 8). In line with such fulfillment, PS has
been found capable of evoking multiple signaling
pathways in mediating apoptotic-dependent and
apoptotic-independent activities [38, 46], making
itself a suitable anti-metastatic therapeutic regimen
to target circulating tumor cells [6, 47]. Moreover, PS
has better anti-tumor potency than resveratrol due to
its superior bioavailability [23, 48]. Furthermore, re-
cent in vivo safety analyses further revealed that PS,
as a major natural product in our daily foods, does
no harm to mice [49] and humans [50], suggesting
that PS may be a useful therapeutic agent by either
systemic or oral administration for the prevention
and treatment of lung metastasis. In this regard,
comparable oral administrative dosages of PS as used
in our studies have also been tested in mice for the
efficacies of anti-tumor growth and anti-oxidant ac-
tivity [23, 51].
Conclusions
Our studies demonstrated a dramatic inhibition of FN
polymerization on suspended LLC cells receiving
shFN and PS treatments. Both AKT- and ERK-
regulated signaling pathways are involved in the PS-
suppressed polyFN assembly on suspended cancer
cells. Intravenous administration of the FN-silenced
or PS-treated tumor cells in turn resulted in a reduc-
tion of metastatic nodules in mouse lungs. When PS
was orally given, it possibly exerted multiple functions
by concomitantly triggering apoptosis-independent
mechanisms to prevent CTC metastasis and inducing
apoptosis in tumor cells already established in the
lungs. Altogether, we propose that both the induction
of apoptosis in solid tumor cells and blockade of
polyFN assembly on circulating tumor cells by PS are
potent therapeutic strategies for the prevention and
treatment of lung cancer metastasis (Fig. 9).
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